Table 4. Sensitivities and specificities corresponding to the suggested risk thresholds for the investigated risk prediction models and the National Lung Screening Trial criteria for 6-y lung cancer incidence in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial chest radiography arm.

Measure	NLST criteria	Bach model	LLP model	Simplified LLP model	PLCOm2012 model	Simplified PLCOm2012 model	TSCE incidence model	Knoke model	TSCE CPS lung cancer death model	TSCE NHS/HPFS lung cancer death model
Sensitivity	71.4% (68.0%–74.6%)	80.0% (76.9%–82.8%)	73.9% (70.6%–77.0%)	74.0% (70.7%–77.1%)	83.0% (80.2%–85.6%)	80.0% (76.9%–82.8%)	79.8% (76.8%–82.6%)	78.1% (75.0%–81.0%)	72.7% (69.3%–75.8%)	78.5% (75.4%–81.4%)
Specificity	62.2% (61.7%–62.7%)	62.4% (61.9%–62.8%)	62.2% (61.8%–62.7%)	62.6% (62.1%–63.1%)	62.5% (61.9%–62.8%)	62.4% (61.9%–62.8%)	62.3% (61.9%–62.8%)	62.2% (61.7%–62.7%)	62.2% (61.7%–62.7%)	62.3% (61.8%–62.8%)

Data given as percent (95% confidence interval).

CPS, Cancer Prevention Study; HPFS, Health Professionals Follow-up Study; LLP, Liverpool Lung Project; NHS, Nurses’ Health Study; NLST, National Lung Screening Trial; TSCE, Two-Stage Clonal Expansion.